Skip to main content

Genetically engineered human pluripotent stem cells, functionalized silk-fibroin platforms and bio-inks: a novel solution for large-scale ex-vivo platelet production, transfusion and drug research

Objective

"The demand for human platelets (plts) for medical research and clinical applications is massive. The primary goal of SilkFUSION is to engineer groundbreaking 3D nanotechnologies for large-scale production of blood plts for human transfusion from human pluripotent stem cells (hPSCs). Our hypothesis is that plt production ex-vivo can be optimized by providing megakaryocytes (Mks) with the correct physical and biochemical environment.

To prove this, we will develop a unique technological platform by engineering non-thrombogenic silk-fibroin biomaterial with proteins, that were proven to promote a 55-fold gain in plt production, to create a three-dimensional ex-vivo bone marrow model that will enhance plt release from Mks derived from hPSCs. Our platform will include (i) novel applications to study pathogenetic mechanisms in patients with inherited platelet production disorders using genetically modified hPSCs; (ii) screening technology for predicting therapeutic efficacy of drugs for thrombocytopenic patients. The development of this technology will exploit an extremely innovative approach using silk-fibroin as a bio-ink for 3D printing a ""live chip"" containing viable Mks for reproducible drug testing.

Our long-term vision is to foster the production of plts in-vitro for clinical transfusions in humans at a scale and cost that will address current supply challenges regarding (i) immunologically matched products to alloimmunised patients; (ii) “supercharged” platelets with recombinant FVIIa generating plts specifically suited for patients with acute haemorrhage resulting from trauma, surgery and wounded in conflict zones. The successful development and distribution of the SilkFUSION platforms will also offer researchers and clinicians specialized precision instruments and bio-ink kits for determining the safety and efficacy of drugs, reducing costs of ineffective therapies while promoting affordable functional strategies for the development of novel molecules."

Call for proposal

H2020-FETOPEN-2016-2017

See other projects for this call

Sub call

H2020-FETOPEN-1-2016-2017

Coordinator

UNIVERSITA DEGLI STUDI DI PAVIA
Net EU contribution
€ 738 327,49
Address
Strada Nuova 65
27100 Pavia
Italy
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,01

Participants (5)

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
Net EU contribution
€ 688 327,50
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
Region
East of England East Anglia Cambridgeshire CC
INSTITUT GUSTAVE ROUSSY
France
Net EU contribution
€ 688 327,50
Address
Rue Camille Desmoulins 39
94805 Villejuif
Activity type
Research Organisations
Non-EU contribution
€ 0,00
INTEGRATED SYSTEMS ENGINEERING SRL
Italy
Net EU contribution
€ 319 580,63
SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Address
Via Volturno Cedri 80
20816 Brugherio
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
CELLINK AB
Sweden
Net EU contribution
€ 344 163,75
SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Address
Arvid Wallgrens Backe 20
413 46 Goteborg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
Region
Södra Sverige Västsverige Västra Götalands län
 
KNOWLEDGE INNOVATION MARKET S.L.
Spain
Net EU contribution
€ 219 773,13
Address
Calle Venezuela 103 Planta 1 Puerta
08019 Barcelona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00